- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07663604
Assessment of Pain Experience in Fibromyalgia
17 juin 2026 mis à jour par: Zülal TATAR
Assessment of Pain Experience in Fibromyalgia Using Abstract Animations and Graphic Body Maps, and Determinants of Pain Quality
The aim of this study is to assess pain in individuals with fibromyalgia using abstract animations and graphical body maps, and to investigate the determinants of pain quality.
Aperçu de l'étude
Statut
Inscription sur invitation
Les conditions
Type d'étude
Observationnel
Inscription (Estimé)
70
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Şirnak
-
Denizli, Şirnak, Turquie (Türkiye)
- Pamukkale University
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
Méthode d'échantillonnage
Échantillon de probabilité
Population étudiée
The study will be conducted on individuals followed by the Rheumatology Department of Pamukkale University Faculty of Medicine and diagnosed with Fibromyalgia according to the 2016 ACR Fibromyalgia Syndrome diagnostic criteria.
La description
Inclusion Criteria:
- Being 18 years of age or older
- Being female
- Having a diagnosis of fibromyalgia syndrome according to the American Rheumatology Association Criteria
- Not receiving active physiotherapy and rehabilitation treatment
- Volunteering to participate in the study.
Exclusion Criteria:
- Having a serious pathology or disease that could compromise the assessment process or affect clinical decision-making (metastasis, cancer, untreated or unhealed fractures, central nervous system disease or history of diabetes, pain outside the musculoskeletal system)
- Having severe mental and psychological disorders
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Painimation Mobile App
Délai: At baseline (Day 1)
|
An electronic pain assessment tool designed to measure the location, nature, and intensity of pain using "pain animations and graphical images."
Patients use a colorable body image to indicate the areas affected by pain.
They then select from eight animations that represent their pain experiences.
The size, speed, and intensity of these animations can be adjusted to accurately represent pain severity.
Painimation animations are derived from the McGill Pain Questionnaire Short Form.
They were developed through a human-centered design process involving patients with acute and chronic pain, clinicians, researchers, and design students.
The animations correspond to the following pain qualities: "pounding," "shooting," "throbbing," "tingling," "cramping," "burning," "stabbing," and "electrifying."
The area of the body affected by pain will be calculated based on the proportion of selected pixels.
|
At baseline (Day 1)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PainDetect Questionnaire
Délai: At baseline (Day 1)
|
The PainDetect Questionnaire is a simple, self-administered, and convenient screening questionnaire that allows for the identification of neuropathic pain components in patients with chronic pain.
It consists of four main sections.
The total score is calculated by summing the scores from the last three sections and ranges from -1 to 38.
Scores of 12 and below indicate that the neuropathic pain component is unlikely, while scores of 19 and above indicate a high probability of the neuropathic pain component being present.
Scores between 12 and 19 are considered inconclusive.
|
At baseline (Day 1)
|
|
Central Sensitization Scale
Délai: At baseline (Day 1)
|
The Central Sensitization Scale consists of two sections.
Section A comprises 25 items that assess symptoms related to physical and emotional health commonly seen in disorders associated with central sensitization.
Each item is scored on a 5-point Likert scale ranging from (0) "never" to (4) "always," with a total score of 100.
Higher scores indicate a higher level of symptom presence.
Section B includes 7 diagnoses assessed within the scope of central sensitization syndrome (tension-type headache or migraine, fibromyalgia, irritable bowel syndrome, restless legs syndrome, temporomandibular joint disorder, chronic fatigue syndrome, and multiple chemical sensitivities) and three additional diagnoses reported to be associated with central sensitization (depression, anxiety or panic attacks, and neck injury).
Participants are asked the following question: "Have you been diagnosed by a doctor with any of the following conditions?" and the year of diagnosis is indicated.
|
At baseline (Day 1)
|
|
Pain Catastrophizing Scale
Délai: At baseline (Day 1)
|
The Pain Catastrophizing Scale is a scale used to assess the psychological aspects of pain-related symptoms in three dimensions: rumination, helplessness, and amplification.
The scale includes 13 items related to specific emotions and thoughts defined as negative associations.
Five of these items relate to rumination, six to helplessness, and two to amplification.
Patients are asked how frequently they recall each thought in these items.
Each item is scored between 0-4, and the total score is calculated between 0-52.
|
At baseline (Day 1)
|
|
Brief Pain Inventory
Délai: At baseline (Day 1)
|
The Brief Pain Inventory is a short, easy-to-administer assessment method that can be used to evaluate pain.
It consists of two sections: pain intensity and impairment caused by pain.
It has 4 items related to pain intensity and 7 items related to impairment caused by pain.
Each item is rated on a scale of 0 to 10.
The total score for both sections is calculated by summing the scores given to each item and dividing the sum by the number of questions, and ranges from 0 to 10. Higher scores indicate more pain and greater impairment caused by pain.
|
At baseline (Day 1)
|
|
Fatigue Severity Scale
Délai: At baseline (Day 1)
|
Published by Krupp in 1989, the FSS consists of nine items.
For each item, the patient is asked to choose a number between 1 and 7 indicating how much they agree with the statement; 1 means strongly disagree, and 7 means strongly agree.
Generally, scores of 4 and above indicate severe fatigue.
|
At baseline (Day 1)
|
|
The Short Form-12 Health Questionnaire
Délai: At baseline (Day 1)
|
A summary version of the Short Form-36 Health Questionnaire, the SF-12 can also be divided into physical and mental sections and consists of a total of 12 questions.
The physical component of the scale is scored between 24 and 56 points, while the mental component is scored between 19 and 60 points.
Higher scores on the scale indicate a higher quality of life.
|
At baseline (Day 1)
|
|
Hospital Anxiety and Depression Scale
Délai: At baseline (Day 1)
|
The Hospital Anxiety and Depression Scale is a 14-item, two-factor scale that assesses patients' anxiety and depression levels.
Seven of these items assess anxiety, and the other seven assess depression.
Each item is scored on a four-point scale.
The total score for anxiety and depression ranges from 0 to 21. Scores between 0 and 7 indicate a normal emotional state.
Scores above 7 on either the anxiety or depression subscales have been reported to indicate the presence of anxiety and depressive disorders.
|
At baseline (Day 1)
|
|
Revised Fibromyalgia Impact Questionnaire
Délai: At baseline (Day 1)
|
The Revised Fibromyalgia Impact Questionnaire is a questionnaire evaluating limitations and functional disability in patients with fibromyalgia.
It consists of 21 questions divided into three sections: function, general, and symptoms.
All questions are rated on a numerical scale from 0 to 10.
A score of 70 or higher indicates severe disability in this patient group.
Higher scores indicate greater fibromyalgia-related disability.
|
At baseline (Day 1)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
3 février 2026
Achèvement primaire (Estimé)
3 avril 2027
Achèvement de l'étude (Estimé)
24 juin 2027
Dates d'inscription aux études
Première soumission
17 juin 2026
Première soumission répondant aux critères de contrôle qualité
17 juin 2026
Première publication (Réel)
23 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
23 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
17 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Painanimation
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .